Valiant Laboratories Limited has informed the Exchange regarding Board meeting held on November 11, 2025 for Audited Standalone And Consolidated Financial Results for the Quarter and Half Year ended September 30, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories Limited informed the stock exchange that its Board of Directors met on November 11, 2025. The Board considered and approved the audited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 and H1 FY26). The announcement is purely an intimation of the board meeting and does not itself disclose the actual financial numbers, segment performance, or commentary from management. Investors will need to refer to the separate financial results filing for detailed revenue, profit, and margin figures.
No direct price impact from this intimation alone; it is a routine regulatory disclosure. Shareholders should watch the actual results filing for revenue, profit, and margin trends that could influence sentiment.